Denise Nardelli-Haefliger

Dr. Denise Nardelli-Haefliger


Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MCMathieu F. Chevalier
Mathieu F. Chevalier
STSara Trabanelli
Sara Trabanelli
JRJulien Racle
Julien Racle
BSBérengère Salomé
Bérengère Salomé
VCValérie Cesson
Valérie Cesson
LDLaurent Derré
Laurent Derré
Non-muscle–invasive bladder cancer (NMIBC) is a highly recurrent tumor despite intravesical immunotherapy instillation with the bacillus Calmette-Guérin (BCG) vaccine. In a prospective longitudinal study, we took advantage of BCG instillations, which increase local immune infiltration, to characterize immune cell populations in the urine of patients with NMIBC as a surrogate for the bladder tumor microenvironment. We observed an infiltration of neutrophils, T cells, monocytic myeloid-derived suppressor cells (M-MDSCs), and group 2 innate lymphoid cells (ILC2). Notably, patients with a T cell–to-MDSC ratio of less than 1 showed dramatically lower recurrence-free survival than did patients with a ratio of greater than 1. Analysis of early and later time points indicated that this patient dichotomy existed prior to BCG treatment. ILC2 frequency was associated with detectable IL-13 in the urine and correlated with the level of recruited M-MDSCs, which highly expressed IL-13 receptor α1. In vitro, ILC2 were increased and potently expressed IL-13 in the presence of BCG or tumor cells. IL-13 induced the preferential recruitment and suppressive function of monocytes. Thus, the T cell–to-MDSC balance, associated with a skewing toward type 2 immunity, may predict bladder tumor recurrence and influence the mortality of patients with muscle-invasive cancer. Moreover, these results underline the ILC2/IL-13 axis as a targetable pathway to curtail the M-MDSC compartment and improve bladder cancer treatment.

5 August 2003 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
DNDenise Nardelli-Haefliger
Denise Nardelli-Haefliger
DWDaniel Wirthner
Daniel Wirthner
JSJohn T. Schiller
John T. Schiller
DLDouglas R. Lowy
Douglas R. Lowy
AHAllan Hildesheim
Allan Hildesheim
PGPierre De Grandi
Pierre De Grandi
Background: In early-phase trials, a human papillomavirus 16 (HPV16) virus–like particle (VLP) vaccine has been shown to be well tolerated, immunogenic, and protective against HPV16 in women, most of whom were taking oral contraceptives. Previous studies have not determined whether HPV immunization results in specific antibody levels in the human genital tract or whether these levels might vary during contraceptive or ovulatory cycles. Therefore, we determined the levels of total and specific antibodies in the cervical secretions of women who had been immunized with HPV16 VLPs and examined the influence of the menstrual cycle and oral contraceptive use on these levels. Methods: Two groups of women were immunized, seven who were taking oral contraceptives and 11 who were ovulating. After seroconversion, serum and cervical secretions were collected twice weekly for 5 weeks. Total immunoglobulins (IgG and IgA) and vaccine-specific IgGs were determined by enzyme-linked immunosorbent assay. Nonparametric statistical analyses were used to determine the statistical significance of differences in IgG levels between groups, and correlations between serum- and cervical-specific IgG levels were determined by the Spearman correlation coefficient. Results: All participants developed detectable titers of anti-HPV16 VLP IgGs in their cervical secretions after immunization. The cervical titers of specific IgG and total IgGs and IgAs among participants in the contraceptive group were relatively constant throughout the contraceptive cycle. In contrast, the cervical titers of specific IgG and total IgGs and IgAs among participants in the ovulatory group varied during the menstrual cycle, being highest during the proliferative phase, decreasing approximately ninefold around ovulation, and increasing approximately threefold during the luteal phase. Serum- and cervical-specific IgG levels were correlated (r = .86) in women in the contraceptive group but not in women in the ovulatory group (r = .27). Conclusions: The relatively high titer of anti-HPV16 antibodies at the cervix is promising in terms of vaccine efficacy; however, the decrease in antibody titer around ovulation raises the possibility that the HPV16 VLP vaccine might be less effective during the peri-ovulatory phase.

15 December 2011 in Journal of Virology
Verified
Journal Article
Closed access
Stephanie LongetStephanie Longet
Stephanie Longet
JSJohn T. Schiller
John T. Schiller
MBMartine Bobst
Martine Bobst
PJPatrice Jichlinski
Patrice Jichlinski
DNDenise Nardelli-Haefliger
Denise Nardelli-Haefliger
The available virus-like particle (VLP)-based prophylactic vaccines against specific human papillomavirus (HPV) types afford close to 100% protection against the type-associated lesions and disease. Based on papillomavirus animal models, it is likely that protection against genital lesions in humans is mediated by HPV type-restricted neutralizing antibodies that transudate or exudate at the sites of genital infection. However, a correlate of protection was not established in the clinical trials because few disease cases occurred, and true incident infection could not be reliably distinguished from the emergence or reactivation of prevalent infection. In addition, the current assays for measuring vaccine-induced antibodies, even the gold standard HPV pseudovirion (PsV) in vitro neutralization assay, may not be sensitive enough to measure the minimum level of antibodies needed for protection. Here, we characterize the recently developed model of genital challenge with HPV PsV and determine the minimal amounts of VLP-induced neutralizing antibodies that can afford protection from genital infection in vivo after transfer into recipient mice. Our data show that serum antibody levels >100-fold lower than those detectable by in vitro PsV neutralization assays are sufficient to confer protection against an HPV PsV genital infection in this model. The results clearly demonstrate that, remarkably, the in vivo assay is substantially more sensitive than in vitro PsV neutralization and thus may be better suited for studies to establish correlates of protection.

25 June 1987 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SGSusan Gerber-Huber
Susan Gerber-Huber
DNDenise Nardelli-Haefliger
Denise Nardelli-Haefliger
JHJacques-Antoine Haefliger
Jacques-Antoine Haefliger
David N. CooperDavid N. Cooper
David N. Cooper
FGFrançoise Givel
Françoise Givel
WWWalter Wahli
Walter Wahli
In Xenopus laevis four estrogen-responsive genes are expressed simultaneously to produce vitellogenin, the precursor of the yolk proteins. One of these four genes, the gene A2, was sequenced completely, as well as cDNAs representing 75% of the coding region of the gene. From this data the exon - intron structure of the gene was established, revealing 35 exons that give a transcript of 5,619 bp without the poly A-tail. This A2 transcript encodes a vitellogenin of 1,807 amino acids, whose structure is discussed with respect to its function. At the nucleic acid as well as at the protein level no extensive homologies with any sequences other than vitellogenin were observed. Comparison of the amino acid sequence of the vitellogenin A2 molecule with biochemical data obtained from the different yolk proteins allowed us to localize the cleavage products on the vitellogenin precursor as follows : NH 2 - lipovitellin I - phosvitin (or phos-vette II - phosvette I) - lipovitellin II - COOH.

1 April 2014 in Clinical Microbiology Reviews
Verified
Journal Article
Open access
SVSam Vasilevsky
Sam Vasilevsky
Gilbert GREUBGilbert GREUB
Gilbert GREUB
DNDenise Nardelli-Haefliger
Denise Nardelli-Haefliger
DBDavid Baud
David Baud
SUMMARY: Chlamydia trachomatisis the leading cause of bacterial sexually transmitted disease worldwide, and despite significant advances in chlamydial research, a prophylactic vaccine has yet to be developed. This Gram-negative obligate intracellular bacterium, which often causes asymptomatic infection, may cause pelvic inflammatory disease (PID), ectopic pregnancies, scarring of the fallopian tubes, miscarriage, and infertility when left untreated. In the genital tract,Chlamydia trachomatisinfects primarily epithelial cells and requires Th1 immunity for optimal clearance. This review first focuses on the immune cells important in a chlamydial infection. Second, we summarize the research and challenges associated with developing a chlamydial vaccine that elicits a protective Th1-mediated immune response without inducing adverse immunopathologies.

1 October 1997 in Developmental Biology
Verified
Journal Article
Open access
PDF file
MKMatthew J. Kourakis
Matthew J. Kourakis
VMViraj A. Master
Viraj A. Master
DLDenise K. Lokhorst
Denise K. Lokhorst
DNDenise Nardelli-Haefliger
Denise Nardelli-Haefliger
CWCathy J. Wedeen
Cathy J. Wedeen
MSMarty Shankland
Marty Shankland
Molecular developmental studies of fly and mouse embryos have shown that the identity of individual body segments is controlled by a suite of homeobox-containing genes called the Hox cluster. To examine the conservation of this patterning mechanism in other segmented phyla, we here describe four Hox gene homologs isolated from glossiphoniid leeches of the genusHelobdella.Based on sequence similarity and phylogenetic analysis, the leech genesLox7, Lox6, Lox20,andLox5are deemed to be orthologs of theDrosophilageneslab, Dfd, Scr,andAntp,respectively. Sequence similarities betweenLox5andAntpoutside the homeodomain and phylogenetic reconstructions suggest that the Antennapedia family of Hox genes (as defined by Bürglin, 1994) had already expanded to include at least two discreteAntpandUbx/abdAprecursors prior to the annelid/arthropod divergence.In situhybridization reveals that the fourLoxgenes described in this study are all expressed at high levels within the segmented portion of the central nervous system (CNS), with variable levels of expression in the segmental mesoderm. Little or no expression was seen in peripheral ectoderm or endoderm, or in the unsegmented head region (prostomium). EachLoxgene has a distinct anterior expression boundary within one of the four rostral segments, and the anterior-posterior (AP) order of these expression boundaries is identical to that reported for the orthologous Hox gene products in fly and mouse. This finding supports the idea that the process of AP axis differentiation is conserved among the higher metazoan phyla with respect to the regional expression of individual Hox genes along that axis. One unusual feature of leech Hox genes is the observation that some genes are only expressed during later development -- beginning at the time of terminal cell differentiation -- whereas others begin expression at a much earlier stage, and their RNA ceases to be detectable shortly after the onset of expression of the ‘late’ Hox genes. The functional significance of this temporal disparity is unknown, but it is noteworthy that only the two ‘early’ Hox genes display high levels of mesodermal expression.